Skip to content
Peptigraph home

ARA-290

EPO-derived peptide. ARA-290 is Not FDA approved · research chemical; research-chemical versions are not the approved drug.

Also called:cibinetide
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusNot FDA approved · research chemicalWADA status unclearFull legal history

Key facts

How we verify
Class
EPO-derived peptide
Also called
cibinetide
Half-life
~2 min
plasma (route not stated in abstract), in people · Pharmacology & therapeutics 2015, PMID 25728128
FDA status
Not FDA approved · research chemical
No approved product found
WADA
Unclear
Not named on the 2026 list
Everything on ARA-290

ARA-290 guides

DosageDoses used in published studies, with the source for each.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

ARA-290: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Any condition (no goal ledger yet)Not in our ledgerNot in our ledger12Human RCT evidence, 4 of 4Investigative ophthalmology & visual science 2017, PMID 28475703

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Common questions

Is ARA-290 FDA approved?

ARA-290 is Not FDA approved · research chemical. Products sold as research chemicals are not the approved drug and are not checked by the FDA.

Sources

  1. 1US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ARA-290" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  4. 4US compounding: Cibinetide (ARA-290) is listed in FDA's 503A category 3 (nominated without adequate support).U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  5. 5Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
  6. 6Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacology & therapeutics · 2015PMID 25728128Accessed 2 Oct 2026
  7. 7PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (sarcoidosis[tiab] OR neuropath*[tiab] OR patients[tiab] OR randomized[tiab]) (29 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.